American Lung Association Launches Bronchiectasis Awareness Initiative with Boehringer Ingelheim Support — American Lung Association

Event summary

American Lung Association launched a bronchiectasis awareness initiative on World Bronchiectasis Day (July 1, 2026).
The disease affects 350,000–500,000 adults in the U.S. and is often misdiagnosed as COPD.
No cure exists for bronchiectasis, but early diagnosis and treatment can improve quality of life.
Initiative aims to educate patients on flare-up prevention and advocate for specialized care.

The big picture

The initiative underscores the persistent challenges in diagnosing and managing chronic lung diseases. With Boehringer Ingelheim's support, the American Lung Association aims to bridge gaps in patient education and specialized care access—a critical move as bronchiectasis cases rise. The collaboration highlights growing industry focus on under-diagnosed respiratory conditions.

What we're watching

Diagnosis Accuracy: Whether the initiative can reduce misdiagnosis rates by clarifying distinctions between bronchiectasis and COPD.
Treatment Innovation: The pace at which new treatment options emerge as awareness grows.
Patient Outcomes: How specialized care access impacts long-term quality of life for bronchiectasis patients.